BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 23850652)

  • 1. Impact of graft-versus-host disease prophylaxis on outcomes after myeloablative single-unit umbilical cord blood transplantation.
    Sanz J; Picardi A; Hernández Boluda JC; Martín C; Ferrá C; Nozzoli C; Gonzalez-Vicent M; Rambaldi A; Valcarcel D; Verdeguer A; Serrano D; de Heredia CD; Pascual MJ; de Paz R; Montesinos P; Bartolozzi B; Algarotti A; Sanz MA; Arcese W; Sanz GF;
    Biol Blood Marrow Transplant; 2013 Sep; 19(9):1387-92. PubMed ID: 23850652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Unrelated umbilical cord blood transplantation with TBI/Ara-c/CY non-ATG conditioning regimen for adults with hematologic malignancies].
    Sun ZM; Liu HL; Geng LQ; Zhou CY; Wang XB; Ding KY; Tong J; Zhu WB; Liu X; Wang ZY
    Zhonghua Yi Xue Za Zhi; 2012 Jun; 92(24):1660-4. PubMed ID: 22944153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen.
    Sanz J; Boluda JC; Martín C; González M; Ferrá C; Serrano D; de Heredia CD; Barrenetxea C; Martinez AM; Solano C; Sanz MA; Sanz GF;
    Bone Marrow Transplant; 2012 Oct; 47(10):1287-93. PubMed ID: 22327127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of intensified myeloablative conditioning regime without antithymocytic globulin (ATG) with myeloablative conditioning regime for single-unit unrelated umbilical cord blood transplantation in hematological malignancies].
    Sun ZM; Liu HL; Wu Y; Geng LQ; Zheng CC; Tang BL; Zhu XY; Tong J; Wang XB; Ding KY; Wan X; Zhang L; Yao W; Zhang XH; Han YS; Yang HZ; Liu X; Zhu WW; Wu JS; Wang ZY
    Zhonghua Yi Xue Za Zhi; 2016 Jul; 96(28):2214-9. PubMed ID: 27480651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
    Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-unit umbilical cord blood transplantation from unrelated donors in adult patients with chronic myelogenous leukemia.
    Sanz J; Montesinos P; Saavedra S; Lorenzo I; Senent L; Planelles D; Larrea L; Martín G; Palau J; Jarque I; Martínez J; de la Rubia J; Moscardó F; Martinez D; Gómez I; López M; Sanz MA; Sanz GF
    Biol Blood Marrow Transplant; 2010 Nov; 16(11):1589-95. PubMed ID: 20553927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe infections after single umbilical cord blood transplantation in adults with or without the co-infusion of CD34+ cells from a third-party donor: results of a multicenter study from the Grupo Español de Trasplante Hematopoyético (GETH).
    Martino R; Bautista G; Parody R; García I; Esquirol A; Rovira M; Cabrera JR; Regidor C; Fores R; García-Marco JA; Serrano D; Barba P; Heras I; Marquez-Malaver FJ; Sánchez-Ortega I; Duarte R; Saavedra S; Sierra J; Vazquez L;
    Transpl Infect Dis; 2015 Apr; 17(2):221-33. PubMed ID: 25652036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience.
    Wall DA; Carter SL; Kernan NA; Kapoor N; Kamani NR; Brochstein JA; Frangoul H; Goyal RK; Horan JT; Pietryga D; Wagner JE; Kurtzberg J;
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):637-46. PubMed ID: 16041314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durable Chimerism and Long-Term Survival after Unrelated Umbilical Cord Blood Transplantation for Pediatric Hemophagocytic Lymphohistiocytosis: A Single-Center Experience.
    Patel SA; Allewelt HA; Troy JD; Martin PL; Driscoll TA; Prasad VK; Kurtzberg J; Page KM; Parikh SH
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1722-1728. PubMed ID: 28647558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative outcomes between cord blood transplantation and bone marrow or peripheral blood stem cell transplantation from unrelated donors in patients with hematologic malignancies: a single-institute analysis.
    Chen YH; Xu LP; Liu DH; Chen H; Zhang XH; Han W; Wang FR; Wang JZ; Wang Y; Huang XJ; Liu KY
    Chin Med J (Engl); 2013 Jul; 126(13):2499-503. PubMed ID: 23823825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unrelated umbilical cord blood transplantation in adult patients.
    Long GD; Laughlin M; Madan B; Kurtzberg J; Gasparetto C; Morris A; Rizzieri D; Smith C; Vredenburgh J; Halperin EC; Broadwater G; Niedzwiecki D; Chao NJ
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):772-80. PubMed ID: 14677117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of unrelated umbilical cord blood transplantation for X-linked adrenoleukodystrophy.
    Beam D; Poe MD; Provenzale JM; Szabolcs P; Martin PL; Prasad V; Parikh S; Driscoll T; Mukundan S; Kurtzberg J; Escolar ML
    Biol Blood Marrow Transplant; 2007 Jun; 13(6):665-74. PubMed ID: 17531776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation.
    Bejanyan N; Rogosheske J; DeFor TE; Lazaryan A; Arora M; Holtan SG; Jacobson PA; MacMillan ML; Verneris MR; Blazar BR; Weisdorf DJ; Wagner JE; Brunstein CG
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):2025-2030. PubMed ID: 27519278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies: results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicenter prospective clinical trial.
    Falda M; Busca A; Baldi I; Mordini N; Bruno B; Allione B; Rambaldi A; Morello E; Narni F; Santarone S; Locatelli F; Bacigalupo A;
    Am J Hematol; 2007 Oct; 82(10):863-6. PubMed ID: 17616972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine.
    Giannotti F; Labopin M; Shouval R; Sanz J; Arcese W; Angelucci E; Sierra J; Santasusana JR; Santarone S; Benedetto B; Rambaldi A; Saccardi R; Blaise D; Carella MA; Rocha V; Baron F; Mohty M; Ruggeri A; Nagler A
    J Hematol Oncol; 2018 Aug; 11(1):110. PubMed ID: 30165887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cord blood transplantation from unrelated donors in adults with high-risk acute myeloid leukemia.
    Sanz J; Sanz MA; Saavedra S; Lorenzo I; Montesinos P; Senent L; Planelles D; Larrea L; Martín G; Palau J; Jarque I; Martínez J; de la Rubia J; Moscardó F; Romero M; Luna I; Montava A; Cañabate S; Sanz GF
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):86-94. PubMed ID: 19744570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia.
    Hsu J; Artz A; Mayer SA; Guarner D; Bishop MR; Reich-Slotky R; Smith SM; Greenberg J; Kline J; Ferrante R; Phillips AA; Gergis U; Liu H; Stock W; Cushing M; Shore TB; van Besien K
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):359-365. PubMed ID: 29128555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.